A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis

Lung India

Volumn 32, Issue 4, 2015, Pages 331-338

  Patil, Jagadevappa ^a   Devi, V ^b   Devi, Kshama ^b   Sarasija, S ^b,c  

^a VT's Shivajirao S Jondhle College of Pharmacy   (India)

^b AL AMEEN COLLEGE OF PHARMACY   (India)

^c NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Freeze dried liposomes; intra tracheal instillation; nebulization; pulmonary delivery; rifampicin; tuberculosis

Indexed keywords

CIPROFLOXACIN; LIPOSOME; RIFAMPICIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLLOID; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INSTILLATION; DRUG SOLUBILITY; DRY POWDER; FEMALE; FREEZE DRYING; IN VITRO STUDY; IN VIVO STUDY; LUNG TUBERCULOSIS; MALE; NONHUMAN; RANDOMIZATION; RAT; SINGLE DRUG DOSE; SURFACE PROPERTY;

EID: 84944884845     PISSN: 09702113     EISSN: 0974598X     Source Type: Journal    
DOI: 10.4103/0970-2113.159559     Document Type: Article

References (25)

1. Patil JS, Sarasija S. Pulmonary drug delivery strategies: A concise, systematic review. Lung India 2012;29:44-9.
2. Hardy JG, Chadwick TS. Sustained release drug delivery to the lungs: An option for the future. Clin Pharmacokinet 2000;39:1-4.
3. Suarez S, Hickey AJ. Drug properties affecting aerosol behavior. Respir Care 2000;45:652-66.
4. Lange CF, Hancock RE, Samuel J, Finlay WH. In vitro aerosol delivery and regional airway surface liquid concentration of a liposomal cationic peptide. J Pharm Sci 2001;90:1647-57.
5. Quenelle DC, Winchester GA, Staas JK, Barrow EL, Barrow WW. Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid. Antimicrob Agents Chemother 2001;45:1637-44.
6. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et al. Heteroresistance to colistin in multidrug-resistant Acinitobacter baumannii. Antimicrob Agents Chemother 2006;50:2946-50.
7. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007;51:3781-8.
8. Patil JS, Suresh S. Physicochemical characterization, in vitro release and permeation studies of resipirable rifampicin-cyclodextrin inclusion complexes. Indian J Pharm Sci 2009;71:638-43.
9. Zaru M, Sinico C, De Logu A, Caddeo C, Lai F, Manca ML, et al. Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: In vitro and in vivo evaluation. J Liposome Res 2009;19:68-76.
10. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG. Liposomes for drug delivery to the lungs by nebulization. Eur J Pharm Biopharm 2007;67:655-66.
11. Voss A, Finlay WH. Deagglomeration of dry powder pharmaceutical aerosols. Int J Pharm 2003;248:39-50.
12. Coates MS, Fletcher DF, Chan HK, Raper JA. Effects of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length. J Pharm Sci 2004;11:2863-76.
13. Cipolla D, Farr SJ, Gonda I, Otulana B. Delivery of biologics to the lung. In: Hansel TT, Barnes PJ, editors. New Drugs for Asthma, Allergy and COPD: Progress in Respiratory Research, CT Bolliger, editor. Vol. 31. Switzerland: Karger Publisher; 2001. p. 20-33.
14. Nagarsenker MS, Londhe VY. Preparation and evaluation of a liposomal formulation of sodium cromoglicate. Int J Pharm 2003;251:49-56.
15. Glavas-Dodov M, Fredro-Kumbaradzi E, Goracinova K, Simonoska M, Calis S, Trajkovic-Jolevska S, et al. The effect of lyophilization on the stability of liposomes containing 5-FU. Int J Pharm 2005;291:79-86.
16. Jakobsen DF, Frokjaer S, Larsen C, Niemann H, Buur A. Application of isothermal micro-calorimetry in preformulation: Hygrosopicity of drug substances. Int J Pharm 1997;156:67-77.
17. Dubernet C. Thermoanalysis of microspheres. Thermo Chim Acta 1995;248:259-69.
18. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001;48:5-16.
19. O'Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization. Pharm Res 2000;17:955-61.
20. Davies NM, Feddah MR. A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm 2003;255:175-87.
21. Sanna V, Kirschvink N, Gustin P, Gavini E, Roland I, Delattre L, et al. Preparation and in vivo toxicity study of solid lipid microparticles as carrier for pulmonary administration. AAPS PharmSciTech 2003;5:e27.
22. Garcia-Contreras L, Morçöl T, Bell SJ, Hickey AJ. Evaluation of novel particles as pulmonary delivery systems for insulin in rats. APPS Pharm Sci 2003;5:E9.
23. Shahiwala A, Misra A. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: A technical note. AAPS Pharm Sci Tech 2005;6:E482-6.
24. Enna SJ, Schanker LS. Absorption of drugs from the rat lung. Am J Physiol 1972;223:1227-31.
25. Hemanth Kumar AK, Chandra I, Geetha R, Chelvi KS, Lalitha V, Prema G. A validated high-performance liquid chromatography method for the determination of rifampicin and desacetyl rifampicin in plasma and urine Indian J Pharmacol 2004;36:231-3.